Business
First tazarotene lotion treatment for acne vulgaris, ARAZLO(TM) (tazarotene lotion, 0.045%), now available to patients through Quebec, Ontario, Alberta, Saskatchewan and federal NIHB public drug plans
First tazarotene lotion treatment for acne vulgaris, ARAZLO™ (tazarotene lotion, 0.045%), ...
About this update from Bausch Health Companies Inc.
[{"type":"text","content":"\n \n \n \n First tazarotene lotion treatment for acne vulgaris, ARAZLO™ (tazarotene lotion, 0.045%), now available to patients through Quebec, Ontario, Alberta, Saskatchewan and federal NIHB public drug plans\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n \n LAVAL, QC\n \n \n ,\n \n \n Dec. 22, 2022\n \n \n /CNW Telbec/ - Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC) and its Canadian dermatology division, one of the largest prescription dermatology health care businesses in Canada, today announced that its new topical prescription treatment for acne vulgaris, ARAZLO\n \n TM\n \n (tazarotene lotion, 0.045% w/w), is now available to patients through the provincial public drug plans of\n \n Quebec\n \n ,\n \n Ontario\n \n ,\n \n Alberta\n \n and\n \n Saskatchewan\n \n , as well as the federal government's Non-Insured Health Benefits (NIHB) drug plan, which serves\n \n Canada's\n \n First Nations and Inuit populations.\n \n 1\n \n \n \n \n \n \n \n \n \n \n ARAZLO is the first tazarotene lotion treatment approved by Health Canada for the topical treatment of acne vulgaris in patients 10 years of age and older.\n \n 2\n \n The listings by the four public drug plans are the first for ARAZLO in\n \n Canada\n \n , with others expected to follow as a result of the successful conclusion of listing negotiations with the pan-Canadian Pharmaceutical Alliance, representing the drug plans of the federal government and all provinces and territories.\n \n \n \"We are very pleased to have achieved agreements for these first public drug plan listings in\n \n Canada\n \n for ARAZLO,\" said\n \n Cees Heiman\n \n , Bausch Health, Senior Vice President,\n \n Europe\n \n and\n \n Canada\n \n .  \"It is an important further step in helping to provide new treatment options for the approximately 5.6 million Canadians who are impacted by acne.\n \n 4\n \n We are very proud to have a large dermatology portfolio to help meet Canadians' needs.\"\n \n \n \"While tazarotene is not a new retinoid, the vehicle in ARAZLO is a true i...